| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 356.4 | 308.5 | 15.526 | 349 | 2.12 |
| Gross Profit (Loss) | 117.4 | 98.1 | 19.673 | 112.1 | 4.727 |
| Operational Profit (Loss) | 57.1 | 51.5 | 10.873 | 54.4 | 4.963 |
| Net profit (Loss) | 51.6 | 27.9 | 84.946 | 51.8 | -0.386 |
| Total Comprehensive Income | 52.2 | 28.9 | 80.622 | 53.7 | -2.793 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Sales/Revenue | 1,028.3 | 870.2 | 18.168 |
| Gross Profit (Loss) | 328.3 | 251.8 | 30.381 |
| Operational Profit (Loss) | 161.6 | 108.7 | 48.666 |
| Net profit (Loss) | 154.5 | 40.4 | 282.425 |
| Total Comprehensive Income | 157.1 | 42.9 | 266.2 |
| Total Shareholders Equity (after Deducting Minority Equity) | 1,945.1 | 662 | 193.821 |
| Profit (Loss) per Share | 3.5 | 1.15 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is | Q3 revenue increased by 15.5% year-on-year to SAR 356.4 million, compared to SAR 308.5 million for the same quarter of 2024. This growth was mainly driven by higher inpatient and outpatient volumes at Almoosa Health Company. In Q3, Almoosa Health opened two large medical centres in Al Ahsa and Al Khobar in addition to the expansion of its existing specialty service offerings. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | Net profit for Q3 2025 amounted to SAR 51.6 million, marking a substantial growth from net profit of SAR 27.9 million in Q3 2024, an improvement of over 84.9% year-on-year. This performance was primarily driven by strong revenue growth, supported by increased patient volumes and higher inpatient admissions. Enhanced operational efficiency and effective cost management further contributed to the improved results. |
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is | Q3 2025 revenue reached SAR 356.4 million, reflecting a 2.1% increase over the previous quarter, driven by growth in patient volumes and greater utilization of core medical specialties. |
| The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is | Net profit decreased by -0.3% quarter-over-quarter, from SAR 51.8 million in Q2 2025 to SAR 51.6 million in Q3 2025. The slight drop is primarily due to the additional operational cost for the newly launched medical centers in Q3. These costs are expected to normalize as the ramp-up progresses. |
| The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is | Revenues increased by 18.2% to reach SAR 1,028.3 million for the nine months of 2025, compared to SAR 870.2 million for the same period in 2024. This growth is mainly attributed to strong performance across operating segments, opening of new clinics, higher patient volumes, and improved utilization of medical services. |
| The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is | Net profit surged by 282.6% to SAR 154.5 million for the nine months of 2025, compared to SAR 40.4 million of the same period for the last year. This substantial improvement was mainly driven by higher revenues resulting from increased patient volumes and admissions, improved operational efficiency, and a reduction in finance costs following the loan settlement earlier in the year. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | N/A |
| Reclassification of Comparison Items | N/A |
| Additional Information | Performance Highlights – Q3 2025 - Patient volumes continued to grow in Q3 2025, reflecting sustained demand across inpatient and outpatient services. - Revenue increased by 15.5% YoY to SAR 356.4 million in Q3 2025, compared to SAR 308.5 million in Q3 2024, driven by strong operational performance for both out-patient and In-patient services. - EBITDA improved by 11.2% YoY, reaching SAR 79.8 million in Q3 2025 compared to SAR 71.7 million in Q3 of 2024. - Net profit surged to SAR 51.6 million in Q3 2025, compared to net profit of SAR 27.9 million in Q3 2024 supported by revenue growth, improved operational efficiency and reduced finance costs. The Board has approved a dividend of SAR 0.35 per share, amounting to 15.5 million, for the third quarter of 2025 |
| Attached Documents | Attached Documents Attached Documents |
